Although the efficacy of CDK7 inhibition in endocrine-resistant, palbociclib-resistant breast cancer is currently being investigated (10), little is known as to the potential of targeting the transcriptional regulator CDK9 in ER+ breast cancers. The gene discussed is CDK9; the disease is breast cancer.